YM155 (Sepantronium Bromide)

Catalog No.S1130

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.

Price Stock Quantity  
USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

YM155 (Sepantronium Bromide) Chemical Structure

YM155 (Sepantronium Bromide) Chemical Structure
Molecular Weight: 443.29

Validation & Quality Control

Cited by 41 publications:

12 customer reviews :

Quality Control & MSDS

Related Compound Libraries

YM155 (Sepantronium Bromide) is available in the following compound libraries:

Product Information

  • Compare Survivin Inhibitors
    Compare Survivin Products
  • Research Area

Product Description

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.
Targets Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
IC50 0.54 nM
In vitro YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
Kasumi-1M{j4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnIO|IhcA>?MonISG1UVw>?NH3MWohKSzVyPUCuNFA6KMLzIECuNFAxQSEQvF2=MmnSNlU3PTl5M{G=
M-07eM2DITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjOWWJtPzJiaB?=Ml3sSG1UVw>?NIL1SGZKSzVyPUCuNFQxKMLzIECuNFE{KM7:TR?=MmrXNlU3PTl5M{G=
THP-1NGrLUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFf0c2Q4OiCqMoO2SG1UVw>?MnW5TWM2OD1yLkC1NUDDuSByLkCxN{DPxE1?Mm\6NlU3PTl5M{G=
CMKMonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DTZ|czKGh?M1vPe2ROW09?NFjTWFFKSzVyPUCuNFU{KMLzIECuNFA6KM7:TR?=M13oZVI2PjV7N{Ox
MV4-11MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7ofnc4OiCqNGrPWGRFVVORMo\DTWM2OD1yLkC1OUDDuSByLkCyPEDPxE1?M4fyPVI2PjV7N{Ox
AML-193MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjYXXFMPzJiaB?=MlfnSG1UVw>?MkTyTWM2OD1yLkS2NkDDuSByLkC2NEDPxE1?NW[zUllWOjV4NUm3N|E>
HL-60M4TCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rEe|czKGh?NYL2NGNGTE2VTx?=M4DZfWlEPTB;MD6wNFEhyrFiMD6wNFAzKM7:TR?=MYOyOVY2QTd|MR?=
ML-2M2\pPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF[zfIU4OiCqMoP3SG1UVw>?M3PVWmlEPTB;MD6wNFkhyrFiMD6wNFIh|ryPM{WxUVI2PjV7N{Ox
OCI/AML3NYLqU3piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\yTFczKGh?MVfEUXNQNInycndKSzVyPUCuNFEyKMLzIECuNFAzKM7:TR?=NYnXW5ZzOjV4NUm3N|E>
HELM2nDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3f0OFczKGh?NV;uS|kyTE2VTx?=M4H5WGlEPTB;MD61OVkhyrFiMD6wN|gh|ryPM{TP[|I2PjV7N{Ox
ME-1NGHve5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWS3NkBpMWrEUXNQNHHkU4pKSzVyPUCuOlg1KMLzIECuNVc6KM7:TR?=MlmzNlU3PTl5M{G=
THP-1NE[wSVJCeG:ydH;zbZMhSXO|YYm=Mnv0NeKh|ryPMWK3NkBpNYH0OIJxTE2VTx?=NWHhZ3dEcW6mdXPld{BieG:ydH;zbZM>MXmyOVY2QTd|MR?=
M-07eNGrWNlJHfW6ldHnvckBCe3OjeR?=M{nLTVDjiJNzwrFOwG0>NX3xcW9UPzJiaB?=M1vCSGROW09?M4DXOYlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6=M{HRRVI2PjV7N{Ox
THP-1NEfRcJdHfW6ldHnvckBCe3OjeR?=NYfE[VlkOOLCk{JCpO69VQ>?MmjxO|IhcA>?NGDpT4pFVVORMVTpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmwNVq3NHZ{OjV4NUm3N|E>
CMKMn\DSpVv[3Srb36gRZN{[Xl?M4PScFDjiJNzwrFOwG0>NX7ZS|dwPzJiaB?=MYPEUXNQMnHCbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?=NUXpW|JTOjV4NUm3N|E>
AML-193NYDWdZE2TnWwY4Tpc44hSXO|YYm=MWmw5qCUOcLizszNNHrUXYg4OiCqNV\tU4d5TE2VTx?=M2XqdIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6=M{X5UlI2PjV7N{Ox
Kasumi-1MXzGeY5kfGmxbjDBd5NigQ>?MmiwNQKBmzIEoN88US=>NHjSWYk4OiCqM2rUbWROW09?M{f3WIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6=M2jwRlI2PjV7N{Ox
MV4-11NYnid5EzTnWwY4Tpc44hSXO|YYm=M176XFDjiJNzwrFOwG0>NWP5Z4U5PzJiaB?=M33IfWROW09?MYDpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmwNIDVe24zPTZ3OUezNS=>
MUG-Chor MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTrcWY3OC13IN88US=>M2HzSFI1NzR6IHi=NGqy[4JKSzVyPUeuNFXjiImwTTDmc5IhPDiqM4TKd|I2PjRyMUi1
U-CH1 NGHjVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{e0T|AuPSEQvF2=NXL6VpV{OjRxNEigbC=>M3rvWWlEPTB;OT6wN-KBkW6PIH\vdkA1QGh?NEfkVo0zPTZ2MEG4OS=>
KATOIIIM1njNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUCxNE8zOCCwTR?=NX\4WoMxPDhiaB?=M{jvc4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzMknpNlU3OzVyNUW=
AGS NWLFT2puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVWxNE8zOCCwTR?=MXq0PEBpM1jHTIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzNF32d5QzPTZ|NUC1OS=>
SACC-83M4\hWGZ2dmO2aX;uJGF{e2G7M3rLbVUhdk1?M2XQSlQ5KGh?MmHK[IVkemWjc3XzJI52[2ynYYKg[ZhxemW|c3nvckBw\iCKSV[tNe6yMonhNlU1QDV4M{W=
INA-6NUizepB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDzbHYxNTVyMDDuUS=>MnXhOFghcA>?NFTpb3NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?MWiyOVI6Pjl5OB?=
U-266NWnTTY16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrCfGgxOC13MECgcm0>M1\iSFQ5KGh?M1:5ZolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzNGOwVlEzPTJ7Nkm3PC=>
MOLP-8NXvROIoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW[wMVUxOCCwTR?=MWG0PEBpMoq2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>NIDhTI8zPTJ7Nkm3PC=>
HG-1MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HKW|AuPTByIH7NMVy0PEBpMkflbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>NX;MTm1ZOjV{OU[5O|g>
NCI-H929M37WZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYewMVUxOCCwTR?=NE\lNIY1QCCqMWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>Mn;tNlUzQTZ7N{i=
OPM-2MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;kNE02ODBibl2=Mn3oOFghcA>?MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>M{DqbVI2Ojl4OUe4
L-363M4DFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37aVlAuPTByIH7NM{LIc|Q5KGh?NH\vWGFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?Mn[xNlUzQTZ7N{i=
MOLP-2NGm4d|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzUWIVIOC13MECgcm0>MYG0PEBpMXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>NGP5fWMzPTJ7Nkm3PC=>
KMS-12-BMMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XG[|AuPTByIH7NMo\0OFghcA>?MYTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>NVuwV2xNOjV{OU[5O|g>
SK-MM-2NWP1OppqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnGxNE02ODBibl2=MkXuOFghcA>?M17RdYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzMmnnNlUzQTZ7N{i=
U-266NHnCUXFCeG:ydH;zbZMhSXO|YYm=NITo[WoxNTVyIH7NMX[yOEBpMoq5bY5lfWOnczDhdI9xfG:|aYO=Mn\XNlUzQTZ7N{i=
INA-6 MX\BdI9xfG:|aYOgRZN{[Xl?M3\rblAuPTBibl2=NX31RVNFOjRiaB?=NVuwepM2cW6mdXPld{BieG:ydH;zbZM>M1vXclI2Ojl4OUe4
MCF7NGPBd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnsbY44OiCqMXvJR|UxRTF|INMxJFYhdk1?MWCyOVIzODJ{NR?=
MCF7-TamR6NF6wSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;IUXBIPzJiaB?=M4e1PWlEPTB;ODFCtUA3KG6PMl33NlUzOjB{MkW=
MCF7-TamR7NHjvPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1r2fFczKGh?MYPJR|UxRThiwsGgN{BvVQ>?NUTidWgzOjV{MkCyNlU>
MCF7-TamR8NH3oVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY[3NkBpMnzmTWM2OD1zNTFCtUA3KG6PMmjzNlUzOjB{MkW=
MCF7-TamC3MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTTO|IhcA>?NFTmXGVKSzVyPU[gxtEhOyCwTR?=NY\Tcm8{OjV{MkCyNlU>
MCF7-TamC6NHy4co9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF22dos4OiCqMYPJR|UxRTZiwsGgNE4yKG6PMmP6NlUzOjB{MkW=
MDA-MB-231M4jkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\FO|IhcA>?M4rzWWlEPTB;NTFCtUAyKG6PMkjBNlUzOjB{MkW=
SK-BR-3MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYi3NkBpMoj3TWM2OD15INMxJFAvOyCwTR?=NEX1WnEzPTJ{MEKyOS=>
Eca109NGTqXFlHfW6ldHnvckBCe3OjeR?=NE\Ke|UyNTVyIH7NMlfsOFghcA>?NYPsXoRjTE2VTx?=M1rWfZN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?NFHv[ZUzPTF|OUO5OS=>
TE13M33nSGZ2dmO2aX;uJGF{e2G7Mn;lNU02OCCwTR?=MoD6OFghcA>?M3HxemROW09?NET1R5h{fXCycnXzd4V{KHO3co\peolvKGW6cILld5Nqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?NH3HTJYzPTF|OUO5OS=>
Eca109NWDIbI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXhRWJNOC1zMECgcm0>NU\DSYd6OjRxNEigbC=>NIX4XIRFVVORM1rqZ4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=M1;NW|I2OTN7M{m1
TE13NY\iW4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWCwMVExOCCwTR?=M2jpN|I1NzR6IHi=NETxbZRFVVORMUjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?MYKyOVE{QTN7NR?=
MT-3NYn6UmtOU2mwYYPlJGF{e2G7M325U|czKGh?NXrPUHByTE2VTx?=M3nkZ2lEPTB;Mj64OkDDuSByLkW0JI5OKG[xcjDEVlQh\XiycnXzd4lwdg>?M3PtRVI1QDZ4NUi1
MDA-MB-468NH\UNYRMcW6jc3WgRZN{[Xl?M3fkZVczKGh?MYHEUXNQMVHJR|UxRTBwMUGgxtEhOC5yMTDuUUBnd3JiRGK0JIV5eHKnc4Ppc44>NX;CeIp4OjR6Nk[1PFU>
SUM-159NIDRTXZMcW6jc3WgRZN{[Xl?M1z3fFczKGh?MkTHSG1UVw>?MVTJR|UxRTFwN{KgxtEhOC5|MzDuUUBnd3JiRGK0JIV5eHKnc4Ppc44>MYeyOFg3PjV6NR?=
MT-3NUXWVJdIU2mwYYPlJGF{e2G7MmroO|IhcA>?M323SGROW09?NICwdJVKSzVyPUW0MlEyKMLzIESuN|Ihdk1iZn;yJGRTPSCneIDy[ZN{cW:wNHTB[IczPDh4NkW4OS=>
MDA-MB-468M2fQZWtqdmG|ZTDBd5NigQ>?NX:xdIhJPzJiaB?=M1K3UWROW09?Mo\pTWM2OD1yLkC3JOKyKDBwMEKgcm0h\m:{IFTSOUBmgHC{ZYPzbY9vMnXuNlQ5PjZ3OEW=
SUM-159M{XlRmtqdmG|ZTDBd5NigQ>?NE\zeFY4OiCqM2HteGROW09?NHfBSWtKSzVyPU[5MlQhyrFiND6yN{BvVSCob4KgSHI2KGW6cILld5Nqd25?Mn7qNlQ5PjZ3OEW=
MT-3 + NACMVXLbY5ie2ViQYPzZZk>NHj6Xlc4OiCqMVPEUXNQM1f6TmlEPTB;NU[uNkDDuSB{LkC3JI5OKG[xcjDEVlUh\XiycnXzd4lwdg>?MWCyOFg3PjV6NR?=
MT-3 + SB203580NXrKVI9yU2mwYYPlJGF{e2G7M2OwOlczKGh?NUfDPYt7TE2VTx?=MWDJR|UxRTN6LkSxJOKyKDVwMEKgcm0h\m:{IFTSOUBmgHC{ZYPzbY9vNYLKdllLOjR6Nk[1PFU>
DBM{jjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPuNW0yOCCwTR?=NYSxXIZrOjRiaB?=NGm4eHVFVVORMkfQbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uNUXtd5R{OjR2OE[1PVU>
SU-DHL-8MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnRZ4dWOTBibl2=MVSyOEBpNVvMfFNzTE2VTx?=MV;pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36=MWKyOFQ5PjV7NR?=
WSU-DLCL2M2HtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3FOHFUOTBibl2=NF7yW5QzPCCqM3\vb2ROW09?M{LRRolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=>MWSyOFQ5PjV7NR?=
ACC-2MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPnSoVKOC1zMECgcm0>NUP2O|BsOjRiaB?=MorRbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>MWSyOFM4ODl7NR?=
ACC-2MULBdI9xfG:|aYOgRZN{[Xl?MoHPNE0zOCCwTR?=MmnnNlQhcA>?NWmxXWtKcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>NITVVWIzPDN5MEm5OS=>
ACC-2NV70[VVbTnWwY4Tpc44hSXO|YYm=M2ru[FAuOjBibl2=NXXYS49[OjRiaB?=MVzpcoNz\WG|ZYOgeIhmKGOxbo\ldpNqd25ib3[gUGM{USC2bzDMR|NKUQ>?NF3peW0zPDN5MEm5OS=>
BFTC905NUW5S4RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVOwMVExODBibl2=NWHibmNsPDhiaNMgMoDRSG1UVw>?MnjPTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?NV\5N5Z2OjR{OUe2OFQ>
T24M4DOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnj3NE0yODByIH7NM4rjdlQ5KGkEoB?=MYLEUXNQNFnufIxKSzVyPUKwJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=NIfoN4ozPDJ7N{[0OC=>
TSGH8301 M{jp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYOwMVExODBibl2=NGeyZoM1QCCqwrC=NEG4W4hFVVORMVHJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?M4q0ZVI1Ojl5NkS0
BFTC909M3vUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;oV5hWOC1zMECwJI5ONFvqT3E1QCCqwrC=NX6xSYZZTE2VTx?=NW\VU4FOUUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=NXTxSWRyOjR{OUe2OFQ>
BFTC905NVzteW4xSXCxcITvd4l{KEG|c3H5M3XmTFIxKG6PMWe0PEBpNWLz[5NGTE2VTx?=NIKzR5lqdmS3Y3XzJIFxd3C2b4Ppdy=>MVKyOFI6PzZ2NB?=
BFTC905NGfq[WlHfW6ldHnvckBCe3OjeR?=NHHXfIYzOCCwTR?=M{H3bFQ5KGh?MVTEUXNQM{TNfIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzOELVnJMoWzNlQzQTd4NES=
A2780pMWXGeY5kfGmxbjDBd5NigQ>?MVqwMVExOCCwTR?=M2jWeFI1KGh?M13DO2ROW09?Ml7SbY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLiM2Dp[lI1OjZ{OEe1
A2780cisNVS5N3M{TnWwY4Tpc44hSXO|YYm=Mke1NE0yODBibl2=MWOyOEBpMoX0SG1UVw>?NFj1[JNqdmS3Y3XzJHN2en[rdnnuJIRwf26{ZXf1cIF1cW:wwrC=Ml3oNlQzPjJ6N{W=
A2780pMnfzRZBweHSxc3nzJGF{e2G7NVe5blQ3PS1zMECgcm0>MWCyOE81QCCqMoHNSG1UVw>?NU\jbIsxcW6lcnXhd4V{KGGyb4D0c5NqeyCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?M1j2O|I1OjZ{OEe1
A2780cisNX\LbIsySXCxcITvd4l{KEG|c3H5NW[4VmRyPS1zMECgcm0>M4jkfFI1NzR6IHi=Mn;hSG1UVw>?NET1XZFqdmO{ZXHz[ZMh[XCxcITvd4l{KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzMXGyOFI3Ojh5NR?=
SH-SY5YM4GzRmFxd3C2b4Ppd{BCe3OjeR?=NIrN[YsyNzFyL{GwNEDDvU1?MWm3NkBpMnv0SG1UVw>?NHPFcZhqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>NIX1e3EzPDJ3NEW2NC=>
HL-60M2PQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVW3NuKhcA>?NXnUe3JITE2VTx?=MUHJR|UxRTBwMzDuUS=>NEDB[nIzOzZzOEi2Ni=>
U937 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrm[XY6PzMEoHi=M3Hj[WROW09?MU\JR|UxRTBwODDuUS=>MkPXNlM3OTh6NkK=
HL-60 NIXINpZHfW6ldHnvckBCe3OjeR?=MnzxNeKh|ryPMVy2M|EzNzJ2IHi=MV3EUXNQNFjZV4NqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kB{fXK4aY\pci=>NGLQRmszOzZzOEi2Ni=>
U937 NFXzTnpHfW6ldHnvckBCe3OjeR?=MkXyNeKh|ryPNV7OSWFDPi9zMj:yOEBpMl\ySG1UVw>?MmTIbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gd5Vzfmm4aX6=MkLNNlM3OTh6NkK=
HL-60NH7XbphCeG:ydH;zbZMhSXO|YYm=NFLqOnAxNjFxMTFOwG0>MY[4JIg>MnTlSG1UVw>?M33HVIlv\HWlZYOgZZBweHSxc3nzM4XTUFI{PjF6OE[y
Sk-NEP-1 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHq0XVgyNTFyMECwJI5ONWXyeGZxOjRiaB?=MnHRSG1UVw>?MXvJR|UxRTFyMDDuUS=>MmfONlMzPjd4OUm=
SK-NEP-1 NVzUZllsSXCxcITvd4l{KEG|c3H5NVrwUJVWPTBxMUCwJI5ONYn1WpRiOTJxMkSgbC=>M2XHNmROW09?M1vJZ4lv\HWlZYOgZZBweHSxc3nzMl61NlMzPjd4OUm=
TC-32MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TzN|AvOS1zMECwJI5ONGK3emxGSzVyPUOuNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=MXmyNlk3OTd4Mx?=
TC-71NIr1bmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MViwMlEuOTByMDDuUS=>Mmi1SWM2OD13Lkegcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{MlnINlI6PjF5NkO=
SK-ES-1M3LrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TtblAvOS1zMECwJI5ONUTo[HpKTUN3ME2yMlghdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyM3vhXVIzQTZzN{[z
RD-ESM4jnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HIWVAvOS1zMECwJI5ONHnaXXlGSzVyPU[uNkBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=M3LidlIzQTZzN{[z
HEK293NWflS4ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nQeVAvOS1zMECwJI5OM3GzfWVEPTB;MkOuNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=NYS1dVMyOjJ7NkG3OlM>
M059JNEnCfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrhOGkxNTVyIH7NMnrvOFghcA>?NVrUO|JucW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?MVuyNlc4ODFzMB?=
M059KNVmycm9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mkf4NE02OCCwTR?=M4TmeFQ5KGh?MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>MnLYNlI4PzBzMUC=
M059JNEXZV4dCeG:ydH;zbZMhSXO|YYm=MYizNEBvVQ>?NYHlSZN3OjRiaB?=MULpcoR2[2W|IHHwc5B1d3Orcx?=M3zGTlIzPzdyMUGw
M059KM3fleGFxd3C2b4Ppd{BCe3OjeR?=M1zFSFMxKG6PMXGyOEBpNWHS[2NPcW6mdXPld{BieG:ydH;zbZM>Ml3vNlI4PzBzMUC=
PANC-1M{e4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWiwMlAyNTFyMECgcm0>MmCwOFghcA>?MkKzTWM2OD1|Lk[5JI5ONVPBO|lKOjJ5MkO4O|E>
MIAPaCa-2MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWSwMlAyNTFyMECgcm0>M3zK[lQ5KGh?NGPTRWdKSzVyPUK5MlM3KG6PNGPLbJgzOjd{M{i3NS=>
BxPC-3M1vkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzKNE4xOS1zMECwJI5ONFfxbW81QCCqM4i0dmlEPTB;M{CuNlYhdk1?NVzFbIRLOjJ5MkO4O|E>
PANC-1MkS2SpVv[3Srb36gRZN{[Xl?M2HKS|AuOTByMDDuUS=>M{nvUVI1KGh?MoLzbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDYTWFRKGGwZDDzeZJ3cX[rbjDlfJBz\XO|aX;uM3L0N|IzPzJ|OEex
MIAPaCa-2M3;Ib2Z2dmO2aX;uJGF{e2G7NXTjVoo4OC1zMECwJI5OM4TwVFI1KGh?MVrpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36=M1vPTVIzPzJ|OEex
BxPC-3MXzGeY5kfGmxbjDBd5NigQ>?NV\C[ZdmOC1zMECwJI5OMW[yOEBpMUHpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36=NHLBWmkzOjd{M{i3NS=>
RPMI-7951Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXf2NoJwT0l3ME2zMlIhdk1?NVK1fGNIOjF5M{e1NFI>
SK-MEL-5M1H0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3wR3d7T0l3ME20MlIhdk1?MkW1NlE4Ozd3MEK=
A375MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLEPGtIUTVyPU[uN{BvVQ>?MVSyNVc{PzVyMh?=
SK-MEL-28NEXlb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\pPGdKPTB;Nz62JI5ONUHiUYZnOjF5M{e1NFI>
SK-MEL-2MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLHTVUxRTFzIH7NMWmyNVc{PzVyMh?=
DBNFjvbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLBOFjDqGh?NUDUfFlNT0l3ME2zMlUhdk1?NGj5XoYzOTJ|N{WwPC=>
PfeifferNXrCWI16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVS0POKhcA>?NGjucVhIUTVyPUOuPUBvVQ>?NH7TToYzOTJ|N{WwPC=>
SU-DHL-5M2\EOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;GeVZJPDkEoHi=NYO1ZlI6T0l3ME2wMlI{KG6PMlPNNlEzOzd3MEi=
SU-DHL-8M2[yZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnzVIhkPDkEoHi=NUj1[JhCT0l3ME2xMlQhdk1?M2PGbVIyOjN5NUC4
WSU-DLCL-2M2XYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\6T2Q1QMLiaB?=NYKwXFJtT0l3ME2xMlQhdk1?Ml;DNlEzOzd3MEi=

... Click to View More Cell Line Experimental Data

In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Promoter-luciferase reporter assay A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5'-GCGCGCTCGAGTCTAGACATGCGGATATATTC-3' and 5'-GCGCGAA-GCTTTGGCGGTTAATGGCGCGC-3'. The resulting PCR fragment is digested with XhoI/HindIII and ligated into the XhoI/HindIII cleavage site of the pGL3-Basic vector. The resulting plasmid is named pSUR-luc. DNA sequencing is done on all amplified sequences by a DNA sequencer. The activity of pSUR-luc is confirmed by luciferase assay with transiently transfected HeLa-S3 cells. Luciferase assay is done. The pGL3 control vector, which contains the SV40 promoter and enhancer sequences, is used. HeLa cells are stably transfected with pSUR-luc and pSV2bsr by Lipofect-AMINE 2000. After blasticidin selection at 10 μg/mL, a single colony is chosen based on appropriate luciferase signals and genetic stability over time and named HeLa-SURP-luc. CHO cells are stably transfected with pGL3-control and pSV2bsr. After blasticidin selection at 10 μg/mL, a single colony is chosen based on appropriate luciferase signals and genetic stability over time and named CHO-SV40-luc. Stocked cells from the HeLa-SURP-luc and CHO-SV40-luc clones are used for chemical screening and characterization of YM155. YM155 in DMSO are added to the cells, which had been seeded the previous day on 96-well plastic plates at 5 × 103 per well. Luciferase activity is measured 24 hours later. IC50 is calculated by logistic analysis.

Cell Assay: [1]

Cell lines Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
Concentrations ~ 100 nM
Incubation Time 48 hours
Method Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.

Animal Study: [1]

Animal Models PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
Formulation Dissolved and diluted in saline immediately before administration
Dosages 5 mg/kg
Administration Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Nakahara T, et al. Cancer Res, 2007, 67(17), 8014-8021.

[2] Iwasa T, et al. Clin Cancer Res, 2008, 14(20), 6496-6504.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01100931 Completed NSCLC|Solid Tumors National Cancer Institute (NCI)|National Institutes of He  ...more National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 2010 Phase 1|Phase 2
NCT01038804 Completed Breast Cancer Astellas Pharma Inc December 2009 Phase 2
NCT01023386 Completed Cancer Astellas Pharma Inc November 2009 Phase 1
NCT01009775 Completed Melanoma Astellas Pharma Inc November 2009 Phase 2
NCT01007292 Completed Non-Hodgkins Lymphoma Astellas Pharma Inc November 2009 Phase 2

view more

Chemical Information

Download YM155 (Sepantronium Bromide) SDF
Molecular Weight (MW) 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 55 mg/mL (124.07 mM)
Water 89 mg/mL (200.77 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Saline 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 1H-Naphth[2,3-d]imidazolium, 4,9-dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(2-pyrazinylmethyl)-, bromide (1:1)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Survivin Products

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • Z-VAD-FMK

    Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

  • Pomalidomide

    Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.

    Features:A derivative of thalidomide and up to 10,000 times more potent than thalidomide.

  • Nutlin-3a

    Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

    Features:Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

Recently Viewed Items

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us